The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Combination Therapy for Advanced Urothelial Carcinoma Shows Promise in Early Clinical Trial
A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real-World Setting
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Preoperative Bone Metastases Not Prognostic in mRCC
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Novel Bladder Cancer Salvage Therapy Appears Safe, Effective
Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.
Neoadjuvant Immune-Chemotherapy Has Positive Effect in MIBC Cases
Combination neoadjuvant therapy with nivolumab and gemcitabine-cisplatin in patients with muscle-invasive bladder cancer resulted in significant pathologic downstaging at radical cystectomy, with manageable toxicities.
Intermediate-Risk mRCC Patients Have Heterogeneous Survival Outcomes
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
Metastasectomy Found to Prolong Survival in Selected mRCC Cases
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
CN for mRCC Does Not Up Survival in the Immune Checkpoint Inhibitor Era
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Risky Business: A New Scoring System for Metastatic Renal Cell Carcinoma
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Sterile Pyuria in UTUC Cases Possibly Predicts Intravesical Recurrence
Sterile pyuria may be a marker of inflammation, which is known to influence carcinogenesis.
Variant Histology Predicts Aggressive UTUC
In a study of patients with upper tract urothelial carcinoma, variant vs conventional histology predicted worse survival.
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
Kidney Cancer Risk Tied to Body Size in Early Life
Higher birth weight and overweight in childhood found to predict an increased risk of renal cell carcinoma in adulthood, a large Danish study found.
Distal Ureteral Management Methods Compared in UTUC
Intravesical incision of the bladder cuff may be superior to other distal ureteral management techniques, according to investigators.
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing.
MMR Deficiency Rare in Urothelial Cancers, but Linked to Immune Response
More studies needed to understand role of MMR deficiency as biomarker of immune response.
Want to read more?
Please login or register first to view this content.
